Table q1_q4_2020_prescription_drugs_wac

Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like R*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000166	Redhill Biopharma, Inc.	03/31/2020	71068000110	AEMCOLO (rifamycin sodium), 194 mg delayed released Oral Tablet, 12 Oral Tablets per 1 Box, package size is 1 box	01/01/2020	14.24	171.24	05/03/2025	Single Source Drug	21	None	Started discount process with Pharmacy Distributors, Payers, and For Government Programs	None	No Change Improvements	None	10/18/2019	Cosmo Technologies	None	None	RedHill did not purchase the product from Cosmo, but instead Cosmo purchased 1,714,286 ADS at an agreed value of $12 million as an upfront payment, plus the ADS as part of the 36.3 million investment into RedHill. Please see Supporting Docs for full Press Release details.	157.00	None	2018	144.00	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=345	None
Rx0000166	Redhill Biopharma, Inc.	03/31/2020	71068000111	AEMCOLO (rifamycin sodium), 194 mg delayed released tablet, 36 Oral Tablets per 1 Box, package size is 1 box	01/01/2020	42.72	513.72	05/03/2025	Single Source Drug	1	None	Started discount process with Pharmacy Distributors, Payers, and For Government Programs	None	No Change Improvements	None	10/18/2019	Cosmo Technologies	None	None	RedHill did not purchase the product from Cosmo, but instead Cosmo purchased 1,714,286 ADS at an agreed value of $12 million as an upfront payment, plus the ADS as part of the 36.3 million investment into RedHill. Please see Supporting Docs for full Press Release details.	471.00	None	2018	432.00	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=346	For US Volume, there have been no sales within the US for this product, however the for will not allow a 0, so we are submitting this with a 1.
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2020	71332000101	Tavalisse 100mg tablet, 1 bottle of 60 tablets	02/15/2020	484.00	11246.00	07/27/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party. The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant.
Rx0000239	Rigel Pharmaceuticals, Inc.	09/30/2020	71332000101	Tavalisse 100mg tablet, 1 bottle of 60 tablets	07/07/2020	564.00	11810.00	07/27/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party. The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant.
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2020	71332000201	Tavalisse 150mg tablet, 1 bottle of 60 tablets	02/15/2020	484.00	11246.00	07/27/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party. The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant.
Rx0000239	Rigel Pharmaceuticals, Inc.	09/30/2020	71332000201	Tavalisse 150mg tablet, 1 bottle of 60 tablets	07/07/2020	564.00	11810.00	07/27/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(Columns 14 - 22) TAVALISSE was developed by Rigel Pharmaceuticals; the drug was not acquired from a third party. The information reported is limited to that which is in the public domain or otherwise publicly available. To help clarify blank responses, we have marked the non-public indicator fields, where relevant.
Rx0000158	RISING PHARMA HOLDINGS, INC.	03/31/2020	64980013301	Dipyridamole Oral Tablet 25 MG 100	01/23/2020	78.71	118.41	None	Non-innovator Multiple Source Drug	21648	None	Change in market conditions	None	Change in Market Dynamics.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	03/31/2020	64980013401	Dipyridamole Oral Tablet 50 MG 100	01/23/2020	126.76	190.70	None	Non-innovator Multiple Source Drug	34464	None	Change in market conditions	None	Change in Market Dynamics.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	03/31/2020	64980013501	Dipyridamole Oral Tablet 75 MG 100	01/23/2020	169.62	255.18	None	Non-innovator Multiple Source Drug	29280	None	Change in market conditions	None	Change in Market Dynamics.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	03/31/2020	57237000114	Lansoprazole Delayed-Release Capsules USP, 30 mg Amoxicillin Capsules USP, 500 mg Clarithromycin Tablets USP, 500 mg 112	01/23/2020	437.49	887.49	None	Non-innovator Multiple Source Drug	25000	None	Change in Market Dynamics	None	None	1	None	None	None	None	None	None	None	None	None	None	Change in Market Dynamics. No 5 Yr History. Rising Pharmaceuticals the ANDA drug.
Rx0000321	R-Pharm US, LLC	12/31/2020	70020191001	1 KIT in 1 PACKAGE, COMBINATION * 15 mg in 1 VIAL, SINGLE-USE * 8 mL in 1 VIAL, SINGLE-USE	10/05/2020	143.00	1625.00	03/01/2022	Single Source Drug	5338	None	Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services.	None	None	1	01/01/2016	BMS	None	1	None	1080.62	1080.62	2007	900.00	None	Sales have decreased by ~40% from acquisition to present.
Rx0000321	R-Pharm US, LLC	12/31/2020	70020191101	1 KIT in 1 PACKAGE, COMBINATION * 45mg in 3 VIAL, SINGLE-USE * 8 mL in 1 VIAL, SINGLE-USE	10/05/2020	429.00	4875.00	03/01/2022	Single Source Drug	2762	None	Increases in raw materials and manufacturing cost (since this is manufactured by third party. Additionally, we had increase cost from our 3PL for providing services.	None	None	1	01/01/2016	BMS	None	1	None	3241.86	3241.86	2007	2700.00	None	Sales have decreased by ~40% from acquisition to present.